Alexion (AstraZeneca) Deal History & Licensing Activity
Alexion (AstraZeneca) is a life sciences. Over the past three years, Alexion (AstraZeneca) has been involved in 1 licensing and acquisition transaction, with a primary focus on Other (2 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
50
Top Modality
Other
Focus Area
Solid Tumors
Alexion (AstraZeneca) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Alexion (AstraZeneca) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AI-driven immuno-oncology discovery platform | AstraZeneca | Other | Discovery | option | Jun 2025 |
Alexion (AstraZeneca) Pipeline Focus
Therapeutic areas and modalities where Alexion (AstraZeneca) is most active based on deal history and clinical trial data.
Therapeutic Areas
Alexion (AstraZeneca) Clinical Pipeline
Alexion (AstraZeneca) has 50 active clinical trials across 6 development phases.
16
Unknown
4
Not Applicable
2
Phase 4
10
Phase 1
13
Phase 2
5
Phase 3
See How Your Asset Matches Alexion (AstraZeneca)'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Alexion (AstraZeneca) Licensing & Deal Activity
Alexion (AstraZeneca) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Alexion (AstraZeneca) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Alexion (AstraZeneca) include Solid Tumors (14 deals and trials), Autoimmune (8 deals and trials), Hematological Malignancies (4 deals and trials), and Option Deals (2 deals and trials). In terms of modality, Alexion (AstraZeneca) has shown particular interest in other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alexion (AstraZeneca) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Alexion (AstraZeneca)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.